
<!DOCTYPE html>

<html lang="en">
<head>
	<meta charset="utf-8">
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<title></title>
	<link rel="stylesheet" href="css/li.css" type="text/css" />
	<link rel="stylesheet" href="css/animate.css" type="text/css" />
	<script type="text/javascript" src="js/base.js"></script>
	<script type="text/javascript" charset="utf-8">
		
		var ANIMATION = [];
		
	</script>
</head>
<body class="slide-ref">
    <div id="popup"> 
        <ol>
            <li><span>KALETRA [package insert].</span></li>
            <li><span>Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ritonavir-based <br>regimen is noninferior to twice-daily dosing and results in similar safety and tolerability <br>in antiretroviral-naive subjects through 48 weeks. <em>J Acquir Immune Defic Syndr.</em> 2009;50:474-481.</span></li>
            <li><span>Murphy RL, da Silva BA, Hicks CB, et al. Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1–infected patients. <em>HIV Clin Trials</em>. 2008;9:1-10.</span></li>
            <li><span>National Heart, Lung, and Blood Institute website. ATP III guidelines at-a-glance quick desk reference. National Cholesterol Education Program. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/atglance.pdf. Accessed July 28, 2010. </span></li>
            <li><span>Dubé MP, Stein JH, Aberg J, et al. Guidelines for the evaluation and management <br>of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trial Group. <em>Clin Infect Dis</em>. 2003;37:613-627.</span></li>
            <li><span>Data on file, AbbVie Inc.</span></li>
        </ol>
    </div>
</body>
</html>



